SURVODUTIDE

Dose per Vial/Pen

Latest Research

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.

2026 Jun

Lempesis IG, Dalamaga M

Open

A review of survodutide: a new dual acting agonist.

2026 Mar 19

Yathindra MR, Bhattacharjee A, Pundir N, Patel P, Jacob NE, Jossy PE, Seetharaman R

Open

Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions.

2026 Mar 14

Patil R, Dunn W, Noureddin M, Alkhouri N

Open

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

2026 Mar

Abulehia A, Ayesh H, Ayesh O, Jaber D, Asad T, Itbaisha A, Abugharbieh H, Gharbia R, Abu-Hilal LH, Leon BGC

Open

Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.

2026 Mar

Zimmermann T, Bleymehl K, Haebel P, Perens J, Roostalu U, Hecksher-Sørensen J, Doerr J, Jarosch S, Lam D, Klein H, Pekcec A, Chehimi SN, Crist RC, Reiner BC, Hayes MR, Augustin R

Open

Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.

2026 Mar

Wang B, Huang J, Chen Z

Open

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.

2026 Mar

Long F, Challa TD, Efthymiou V, Klug M, Klein T, Neubauer H, Wolfrum C, Horvath C

Open

Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.

2026 Feb

Rubino DM, Mooney V, van de Walle V, Baanstra D, Daniëls W, Recaldin C, Nadglowski J

Open

IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.

2026 Jan

Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN

Open

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.

2026 Jan

Andonie CR, Abusalameh A, Ismail I, Hodrob T, Ladadweh M, Ayesh H

Open